The European Medicines Agency (EMA) has recommended that a licence should be granted for ozanimod (Zeposia) for people with active relapsing remitting MS. Active is defined as people who are having relapses or have new or enlarging lesions on MRI scans.
The next step in the approval process is for the European Commission to grant the licence, taking into consideration the EMA's recommendation. Ozanimod will then be appraised by NICE and SMC to determine availability in the UK.
NICE has started the appraisal process for ozanimod but has put further work on hold to prioritize support for the coronavirus pandemic. The MS Trust is contributing to the appraisal.
Ozanimod is taken as a tablet, once daily. A low dose is taken initially which is gradually increased over the first week. This reduces the risk of slowing the heart rate.
In a two year clinical trial, ozanimod reduced the risk of relapses by 38% compared to beta interferon (Avonex) and reduced the number of new active lesions seen on MRI.
The most common side effects reported in clinical trials were nasopharyngitis (common cold), reduced white blood cell count, headache, chest infections and urinary tract infections. Ozanimod caused temporary increases in liver enzymes which generally returned to normal levels without the need to stop treatment.
Ozanimod belongs to the same class of drugs as Gilenya (fingolimod). It works by retaining lymphocytes (immune cells) in lymph nodes. The number of lymphocytes reaching the brain is decreased, resulting in a reduced immune attack on nerve cells in the brain and spinal cord.
Ponesimod (Ponvory) for relapsing remitting multiple sclerosis rejected by NICE
13 Oct 2021 - 00:00
The MS Trust is very disappointed that NICE does not recommend ponesimod (Ponvory) as an NHS treatment in England and Wales.
Multiple sclerosis and disease modifying drugs, what are my options?
28 Sep 2021 - 00:00
We interview Dr Sharmilee Gnanapavan, a Consultant Neurologist at Bart's Health to get some answers on what's new in the world of disease modifying drugs and multiple sclerosis.
New report highlights barriers to accessing Sativex across the UK
18 Aug 2021 - 00:00
Fewer than 13% of people in England eligible for Sativex can access it, according to a new report published today. People living in Wales, Scotland and Northern Ireland also face difficulties.
Sign up for updates from us
Keep up-to-date with the latest MS news, explore new research, read the stories of people living with MS, find out practical tips from MS experts, and discover exciting fundraising opportunities.